
C2N Diagnostics
@c2ndiagnostics
C₂N Diagnostics is a specialty diagnostics company with a vision to bring Clarity Through Innovation®.
ID: 1188904215709532160
28-10-2019 19:44:47
338 Tweet
286 Followers
215 Following


New real-world evidence released by ADDF-funded C2N Diagnostics shows that their PrecivityAD2 beta-amyloid #BloodTest helped correctly diagnose #Alzheimers in 87% of cases as compared to using standard assessment tools. Read more about the findings here: bit.ly/3YrEoiS


.FierceBiotech reports on our release of the PrecivityAD2™ blood test for clinical care, a robust #assay w/ high concordance to amyloid PET & CSF fiercebiotech.com/medtech/c2n-di… #AlzheimersDisease

.Alzheimer's News Today reports on study published in ANA Journals that shows the PrecivityAD® blood test significantly influences clinicians’ decisions about whether to treat people with cognitive impairments for #Alzheimer’s disease. alzheimersnewstoday.com/news/precivity…

News from @medicaldevnet about the PrecivityAD2™ blood test that aims to set a new performance standard for blood biomarkers in #Alzheimer’s disease diagnosis w/ combined measures of amyloid beta (aβ42/40) & tau protein (p-tau217/np-tau217) ratios medicaldevice-network.com/news/c2n-diagn…




Congratulations to Randall Bateman our CTAD Lifetime Achievement Award recipient in recognition for his pioneering work in Alzheimer's Disease Research and Plasma Biomarkers in AD diagnostics.




C2N Sr. Medical Advisor Dr. Monane will present his research Gerontological Society of America (GSA) #GSA2023 in Tampa. "Patient Age And Sex Do Not Appear To Influence Decision Making Around Biomarker Testing for Cognitive Impairment.” Session 9550: 11/12, 10:00–11:30 a.m. room 413 #GSA2023 #Alzheimers



Allston Brighton Community Fund is proud to support AllstonBrighton LL. For over 70 years, the Allston Brighton Little League has been part of our community. We can’t wait to hear “play ball!” #baseball #littleleague #AllstonBrighton leaguelineup.com/welcome.asp?ur…


Hats off to our supporters/sponsors/grantors: @MeilleurTechnologies, LantheusNews, Eli Lilly and Company, Alzheimer's Association, Eisai U.S. Neurology, Genentech, The Rainwater Charitable Foundation, Bristol Myers Squibb, Invicro, Life Molecular Imaging, Johnson & Johnson, C2N Diagnostics, Clario, AbbVie, Quanterix Big round of applause

C2N Diagnostics has entered into a non-exclusive agreement in select markets w/ Mayo Clinic Labs for inclusion of C2N’s Precivity™ tests in their test offerings. bit.ly/3XGmZo7#liquid… #precisionmedicine #Alzheimersdisease #MayoClinicLaboratories

Announcing a new DxA investment in C2N Diagnostics for over $7M—its largest investment to-date. This underscores the DxA’s commitment to developing & deploying #novel biomarkers—like #BloodTests—to transform the #Alzheimers diagnostic landscape: bit.ly/3TGx8yu


C2N announces partnership w/ michaeljfox.org to uncover new links b/w #ParkinsonsDisease #LewyBodyDementia & #AlzheimersDisease c2n.com/news-releases/…